Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent …
Boston, MA – Melatonin is known to have cancer-protective properties, and shift work can induce desynchrony of the circadian system, reducing melatonin production. Shift work has been thought to have important health impacts, with evidence linking s…
At the 3rd International Conference on innovative approaches in Head and Neck Oncology (ICHNO), Dr Hanna Rahbek Mortensen and colleagues at hospitals and institutes in Denmark presented results from a large prospective trial, the DAHANCA 6 & 7 study…
MicroRNAs (miRNAs) regulate gene expression by mainly binding to the 3′-UTR of target mRNAs, leading to mRNA degradation or translation inhibition. Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies in China. Many…
COLUMBUS, Ohio — A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers tha…
(SACRAMENTO, Calif.) — Patients with head and neck cancer who have never smoked have much better survival rates after radiation therapy than patients with a history of smoking, new research from UC Davis Cancer Center has found.
The study by A…
COLUMBUS, Ohio — The genes we possess not only determine the color of our eyes and hair and how our bodies grow, they might also influence the changes that occur in tumors when we develop cancer.
A study by researchers at the Ohio State Universi…
The annual “Euromelanoma Day” campaign is designed to prevent skin cancer among the general public. While there has been considerable interest, it has proved difficult to reach out to some of the at-risk groups. As such, new ways of encouraging thes…
Researchers from Ohio State University found that a common pain relief medication seems to increase the effectiveness of a drug used to treat skin cancer. Experiments in mice showed that the combination of celecoxib — a prescription-only non-steroidal anti-inflammatory drug (NSAID) — and a cream commonly used to treat nonmelanoma skin cancer was up to 35 percent more effective in reducing the number of skin cancer tumors than treating such lesions with the cream alone.